108 related articles for article (PubMed ID: 14523275)
1. Phase I/II trial of intravenous recombinant interleukin-2 in HIV-infected children.
Starr SE; McFarland EJ; Muresan P; Fenton T; Pitt J; Douglas SD; Deveikis A; Levin MJ; Rathore MH;
AIDS; 2003 Oct; 17(15):2181-9. PubMed ID: 14523275
[TBL] [Abstract][Full Text] [Related]
2. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
Vogler MA; Teppler H; Gelman R; Valentine F; Lederman MM; Pomerantz RJ; Pollard RB; Cherng DW; Gonzalez CJ; Squires KE; Frank I; Mildvan D; Mahon LF; Schock B;
J Acquir Immune Defic Syndr; 2004 May; 36(1):576-87. PubMed ID: 15097300
[TBL] [Abstract][Full Text] [Related]
3. Role of interleukin-2 in patients with HIV infection.
Pett SL; Kelleher AD; Emery S
Drugs; 2010 Jun; 70(9):1115-30. PubMed ID: 20518579
[TBL] [Abstract][Full Text] [Related]
4. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial.
Davey RT; Murphy RL; Graziano FM; Boswell SL; Pavia AT; Cancio M; Nadler JP; Chaitt DG; Dewar RL; Sahner DK; Duliege AM; Capra WB; Leong WP; Giedlin MA; Lane HC; Kahn JO
JAMA; 2000 Jul; 284(2):183-9. PubMed ID: 10889591
[TBL] [Abstract][Full Text] [Related]
5. Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cell counts of > or = 300/mm3: CPCRA 059.
Abrams DI; Bebchuk JD; Denning ET; Davey RT; Fox L; Lane HC; Sampson J; Verheggen R; Zeh D; Markowitz NP;
J Acquir Immune Defic Syndr; 2002 Mar; 29(3):221-31. PubMed ID: 11873071
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of subcutaneous recombinant interleukin-2 in patients with advanced HIV disease while on zidovudine.
McMahon DK; Armstrong JA; Huang XL; Rinaldo CR; Gupta P; Whiteside TL; Pazin GJ; Tripoli C; Ho M
AIDS; 1994 Jan; 8(1):59-66. PubMed ID: 8011237
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of recombinant interleukin-2 (rIL-2) in patients with advanced HIV-1 infection and blunted immune response to HAART.
Crespo M; Caragol I; Falcó V; Ribera E; Urban S; Pahissa A
Enferm Infecc Microbiol Clin; 2008 Jan; 26(1):27-31. PubMed ID: 18208763
[TBL] [Abstract][Full Text] [Related]
8. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.
Levy Y; Capitant C; Houhou S; Carriere I; Viard JP; Goujard C; Gastaut JA; Oksenhendler E; Boumsell L; Gomard E; Rabian C; Weiss L; Guillet JG; Delfraissy JF; Aboulker JP; Seligmann M
Lancet; 1999 Jun; 353(9168):1923-9. PubMed ID: 10371571
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study--ANRS 082.
Katlama C; Carcelain G; Duvivier C; Chouquet C; Tubiana R; De Sa M; Zagury L; Calvez V; Autran B; Costagliola D;
AIDS; 2002 Oct; 16(15):2027-34. PubMed ID: 12370501
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.
Tambussi G; Ghezzi S; Nozza S; Vallanti G; Magenta L; Guffanti M; Brambilla A; Vicenzi E; Carrera P; Racca S; Soldini L; Gianotti N; Murone M; Veglia F; Poli G; Lazzarin A
J Infect Dis; 2001 May; 183(10):1476-84. PubMed ID: 11319683
[TBL] [Abstract][Full Text] [Related]
11. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with Arnó A; Ruiz L; Juan M; Jou A; Balagué M; Zayat MK; Marfil S; Martínez-Picado J; Martínez MA; Romeu J; Pujol-Borrell R; Lane C; Clotet B
J Infect Dis; 1999 Jul; 180(1):56-60. PubMed ID: 10353861
[TBL] [Abstract][Full Text] [Related]
13. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.
Lalezari JP; Beal JA; Ruane PJ; Cohen CJ; Jacobson EL; Sundin D; Leong WP; Raffanti SP; Wheeler DA; Anderson RD; Keiser P; Schrader SR; Goodgame JC; Steinhart CR; Murphy RL; Wolin MJ; Smith KA
HIV Clin Trials; 2000; 1(3):1-15. PubMed ID: 11590500
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team.
Saag MS; Sonnerborg A; Torres RA; Lancaster D; Gazzard BG; Schooley RT; Romero C; Kelleher D; Spreen W; LaFon S
AIDS; 1998 Nov; 12(16):F203-9. PubMed ID: 9833848
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of HIV infections with antiretroviral drugs and recombinant interleukin-2].
Dragsted UB; Afzelius P; Nielsen SD; Lundgren JD
Ugeskr Laeger; 2000 Oct; 162(42):5614-8. PubMed ID: 11059298
[TBL] [Abstract][Full Text] [Related]
16. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus.
Kovacs JA; Vogel S; Albert JM; Falloon J; Davey RT; Walker RE; Polis MA; Spooner K; Metcalf JA; Baseler M; Fyfe G; Lane HC
N Engl J Med; 1996 Oct; 335(18):1350-6. PubMed ID: 8857018
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of zidovudine-lamivudine combination therapy in vertically HIV-infected antiretroviral-naive children.
Horneff G; Adams O; Wahn V
AIDS; 1998 Mar; 12(5):489-94. PubMed ID: 9543447
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
[TBL] [Abstract][Full Text] [Related]
19. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects.
Angel JB; Jacobson MA; Skolnik PR; Giordano M; Shapiro L; LeBeaut A; Greaves W; Fuchs AC
AIDS; 2000 Nov; 14(16):2503-8. PubMed ID: 11101061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
